Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Review article: Biomedical intelligence

Vol. 154 No. 6 (2024)

Bone health in patients with inflammatory bowel disease

DOI
https://doi.org/10.57187/s.3407
Cite this as:
Swiss Med Wkly. 2024;154:3407
Published
10.06.2024

Summary

Patients with inflammatory bowel disease (IBD) are prone to reduced bone mineral density and elevated overall fracture risk. Osteopenia affects up to 40% of patients with IBD (high regional variability). Besides disease activity, IBD specialists must consider possible side effects of medication and the presence of associated diseases and extraintestinal manifestations. Osteopenia and osteoporosis remain frequent problems in patients with IBD and are often underestimated because of widely differing screening and treatment practices.

Malnutrition, chronic intestinal inflammation and corticosteroid intake are the major pathophysiological factors contributing to osteoporosis. Patients with IBD are screened for osteoporosis using dual-energy X-ray absorptiometry (DXA), which is recommended for all patients with a prolonged disease course of more than three months, with repeated corticosteroid administration, aged >40 years with a high FRAX risk score or aged <40 years with multiple risk factors. From a therapeutic perspective, besides good disease control, vitamin D supplementation and glucocorticoid sparing, several specific osteological options are available: bisphosphonates, receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors (denosumab), parathyroid hormone (PTH) analogues and selective estrogen receptor modulators.

This review provides an overview of the pathophysiology, diagnosis, prevention and treatment of IBD-associated bone loss.

References

  1. Szafors P, Che H, Barnetche T, Morel J, Gaujoux-Viala C, Combe B, et al. Risk of fracture and low bone mineral density in adults with inflammatory bowel diseases. A systematic literature review with meta-analysis. Osteoporos Int. 2018 Nov;29(11):2389–97. 10.1007/s00198-018-4586-6 DOI: https://doi.org/10.1007/s00198-018-4586-6
  2. Chedid VG, Kane SV. Bone Health in Patients With Inflammatory Bowel Diseases. J Clin Densitom. 2020;23(2):182–9. 10.1016/j.jocd.2019.07.009 DOI: https://doi.org/10.1016/j.jocd.2019.07.009
  3. Prieto JM, Andrade AR, Magro DO, Imbrizi M, Nishitokukado I, Ortiz-Agostinho CL, et al. Nutritional Global Status and Its Impact in Crohn’s Disease. J Can Assoc Gastroenterol. 2021 Mar;4(6):290–5. 10.1093/jcag/gwab006 DOI: https://doi.org/10.1093/jcag/gwab006
  4. Cravo M, Guerreiro CS, dos Santos PM, Brito M, Ferreira P, Fidalgo C, et al. Risk factors for metabolic bone disease in Crohn’s disease patients. Inflamm Bowel Dis. 2010 Dec;16(12):2117–24. 10.1002/ibd.21297 DOI: https://doi.org/10.1002/ibd.21297
  5. Reinshagen M. Osteoporosis in inflammatory bowel disease. J Crohns Colitis. 2008 Sep;2(3):202–7. 10.1016/j.crohns.2008.01.005 DOI: https://doi.org/10.1016/j.crohns.2008.01.005
  6. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol. 2007 Apr;7(4):292–304. 10.1038/nri2062 DOI: https://doi.org/10.1038/nri2062
  7. Croft AP, Campos J, Jansen K, Turner JD, Marshall J, Attar M, et al. Distinct fibroblast subsets drive inflammation and damage in arthritis. Nature. 2019 Jun;570(7760):246–51. 10.1038/s41586-019-1263-7 DOI: https://doi.org/10.1038/s41586-019-1263-7
  8. Shim JH, Stavre Z, Gravallese EM. Bone Loss in Rheumatoid Arthritis: Basic Mechanisms and Clinical Implications. Calcif Tissue Int. 2018 May;102(5):533–46. 10.1007/s00223-017-0373-1 DOI: https://doi.org/10.1007/s00223-017-0373-1
  9. Moschen AR, Kaser A, Enrich B, Ludwiczek O, Gabriel M, Obrist P, et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut. 2005 Apr;54(4):479–87. 10.1136/gut.2004.044370 DOI: https://doi.org/10.1136/gut.2004.044370
  10. Ke K, Arra M, Abu-Amer Y. Mechanisms Underlying Bone Loss Associated with Gut Inflammation. Int J Mol Sci. 2019 Dec;20(24):6323. 10.3390/ijms20246323 DOI: https://doi.org/10.3390/ijms20246323
  11. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008 May;473(2):139–46. 10.1016/j.abb.2008.03.018 DOI: https://doi.org/10.1016/j.abb.2008.03.018
  12. Nemeth ZH, Bogdanovski DA, Barratt-Stopper P, Paglinco SR, Antonioli L, Rolandelli RH. Crohn’s Disease and Ulcerative Colitis Show Unique Cytokine Profiles. Cureus. 2017 Apr;9(4):e1177. 10.7759/cureus.1177 DOI: https://doi.org/10.7759/cureus.1177
  13. Kitaura H, Nagata N, Fujimura Y, Hotokezaka H, Yoshida N, Nakayama K. Effect of IL-12 on TNF-alpha-mediated osteoclast formation in bone marrow cells: apoptosis mediated by Fas/Fas ligand interaction. J Immunol. 2002 Nov;169(9):4732–8. 10.4049/jimmunol.169.9.4732 DOI: https://doi.org/10.4049/jimmunol.169.9.4732
  14. Yoshimatsu M, Kitaura H, Fujimura Y, Eguchi T, Kohara H, Morita Y, et al. IL-12 inhibits TNF-alpha induced osteoclastogenesis via a T cell-independent mechanism in vivo. Bone. 2009 Nov;45(5):1010–6. 10.1016/j.bone.2009.07.079 DOI: https://doi.org/10.1016/j.bone.2009.07.079
  15. Bravenboer N, Oostlander AE, van Bodegraven AA. Bone loss in patients with inflammatory bowel disease: cause, detection and treatment. Curr Opin Gastroenterol. 2021 Mar;37(2):128–34. 10.1097/MOG.0000000000000710 DOI: https://doi.org/10.1097/MOG.0000000000000710
  16. Abreu MT, Geller JL, Vasiliauskas EA, Kam LY, Vora P, Martyak LA, et al. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn’s disease. J Clin Gastroenterol. 2006 Jan;40(1):55–63. 10.1097/01.mcg.0000190762.80615.d4 DOI: https://doi.org/10.1097/01.mcg.0000190762.80615.d4
  17. Mauro M, Radovic V, Armstrong D. Improvement of lumbar bone mass after infliximab therapy in Crohn’s disease patients. Can J Gastroenterol. 2007 Oct;21(10):637–42. 10.1155/2007/216162 DOI: https://doi.org/10.1155/2007/216162
  18. Baban YN, Edicheria CM, Joseph J, Kaur P, Mostafa JA. Osteoporosis Complications in Crohn’s Disease Patients: Factors, Pathogenesis, and Treatment Outlines. Cureus. 2021 Dec;13(12):e20564. 10.7759/cureus.20564 DOI: https://doi.org/10.7759/cureus.20564
  19. Frei R, Fournier N, Zeitz J, Scharl M, Morell B, Greuter T, et al. Early Initiation of Anti-TNF is Associated with Favourable Long-term Outcome in Crohn’s Disease: 10-Year-Follow-up Data from the Swiss IBD Cohort Study. J Crohns Colitis. 2019 Sep;13(10):1292–301. 10.1093/ecco-jcc/jjz057 DOI: https://doi.org/10.1093/ecco-jcc/jjz057
  20. Pittet V, Michetti P, Mueller C, Braegger CP, von Känel R, Schoepfer A, et al.; Swiss IBD Cohort Study Group. Cohort Profile Update: The Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). Int J Epidemiol. 2019 Apr;48(2):385–386f. 10.1093/ije/dyy298
  21. Pazianas M, Rhim AD, Weinberg AM, Su C, Lichtenstein GR. The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn’s disease. Ann N Y Acad Sci. 2006 Apr;1068(1):543–56. 10.1196/annals.1346.055 DOI: https://doi.org/10.1196/annals.1346.055
  22. Bernstein M, Irwin S, Greenberg GR. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn’s disease. Am J Gastroenterol. 2005 Sep;100(9):2031–5. 10.1111/j.1572-0241.2005.50219.x DOI: https://doi.org/10.1111/j.1572-0241.2005.50219.x
  23. Veerappan SG, O’Morain CA, Daly JS, Ryan BM. Review article: the effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease. Aliment Pharmacol Ther. 2011 Jun;33(12):1261–72. 10.1111/j.1365-2036.2011.04667.x DOI: https://doi.org/10.1111/j.1365-2036.2011.04667.x
  24. Gravallese EM, Goldring SR, Schett G. The Role of the Immune System in the Local and Systemic Bone Loss of Inflammatory Arthritis. Osteoimmunology: Interactions of the Immune and Skeletal Systems: Second Edition. 2016 Jan 1;241–56. 10.1016/B978-0-12-800571-2.00013-X DOI: https://doi.org/10.1016/B978-0-12-800571-2.00013-X
  25. Aeberli D. Skeleton, Inflammatory Diseases of. Reference Module in Biomedical Sciences. 2014 Jan 1; DOI: https://doi.org/10.1016/B978-0-12-801238-3.00026-X
  26. Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al.; IBD guidelines eDelphi consensus group. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019 Dec;68 Suppl 3:s1–106. 10.1136/gutjnl-2019-318484 DOI: https://doi.org/10.1136/gutjnl-2019-318484
  27. Compston J. Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol. 2010 Feb;6(2):82–8. 10.1038/nrrheum.2009.259 DOI: https://doi.org/10.1038/nrrheum.2009.259
  28. Kogianni G, Mann V, Noble BS. Apoptotic bodies convey activity capable of initiating osteoclastogenesis and localized bone destruction. J Bone Miner Res. 2008 Jun;23(6):915–27. 10.1359/jbmr.080207 DOI: https://doi.org/10.1359/jbmr.080207
  29. Compston J. Glucocorticoid-induced osteoporosis: an update. Endocrine. 2018 Jul;61(1):7–16. 10.1007/s12020-018-1588-2 DOI: https://doi.org/10.1007/s12020-018-1588-2
  30. Gado M, Baschant U, Hofbauer LC, Henneicke H. Bad to the Bone: The Effects of Therapeutic Glucocorticoids on Osteoblasts and Osteocytes. Front Endocrinol (Lausanne). 2022 Mar;13:835720. 10.3389/fendo.2022.835720 DOI: https://doi.org/10.3389/fendo.2022.835720
  31. Shamir R, Phillip M, Levine A. Growth retardation in pediatric Crohn’s disease: pathogenesis and interventions. Inflamm Bowel Dis. 2007 May;13(5):620–8. 10.1002/ibd.20115 DOI: https://doi.org/10.1002/ibd.20115
  32. Tigas S, Tsatsoulis A. Endocrine and metabolic manifestations in inflammatory bowel disease. Ann Gastroenterol. 2012;25(1):37–44.
  33. Katsanos KH, Tsatsoulis A, Christodoulou D, Challa A, Katsaraki A, Tsianos EV. Reduced serum insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 levels in adults with inflammatory bowel disease. Growth Horm IGF Res. 2001 Dec;11(6):364–7. 10.1054/ghir.2001.0248 DOI: https://doi.org/10.1054/ghir.2001.0248
  34. Pappa HM, Grand RJ, Gordon CM. Report on the vitamin D status of adult and pediatric patients with inflammatory bowel disease and its significance for bone health and disease. Inflamm Bowel Dis. 2006 Dec;12(12):1162–74. 10.1097/01.mib.0000236929.74040.b0 DOI: https://doi.org/10.1097/01.mib.0000236929.74040.b0
  35. Giustina A, di Filippo L, Allora A, Bikle DD, Cavestro GM, Feldman D, et al. Vitamin D and malabsorptive gastrointestinal conditions: A bidirectional relationship? Rev Endocr Metab Disord. 2023 Apr;24(2):121–38. 10.1007/s11154-023-09792-7 DOI: https://doi.org/10.1007/s11154-023-09792-7
  36. Weidinger C, Ziegler JF, Letizia M, Schmidt F, Siegmund B. Adipokines and Their Role in Intestinal Inflammation. Front Immunol. 2018 Oct;9(OCT):1974. 10.3389/fimmu.2018.01974 DOI: https://doi.org/10.3389/fimmu.2018.01974
  37. Karaskova E, Velganova-Veghova M, Geryk M, Foltenova H, Kucerova V, Karasek D. Role of Adipose Tissue in Inflammatory Bowel Disease. Int J Mol Sci. 2021 Apr;22(8):4226. 10.3390/ijms22084226 DOI: https://doi.org/10.3390/ijms22084226
  38. Okada M, Imamura K, Fuchigami T, Omae T, Iida M, Nanishi F, et al. [2 cases of nonspecific multiple ulcers of the small intestine associated with osteomalacia caused by long-term intravenous administration of saccharated ferric oxide]. Nihon Naika Gakkai Zasshi. 1982 Nov;71(11):1566–72. 10.2169/naika.71.1566 DOI: https://doi.org/10.2169/naika.71.1566
  39. Schouten BJ, Doogue MP, Soule SG, Hunt PJ. Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia. Ann Clin Biochem. 2009 Mar;46(Pt 2):167–9. 10.1258/acb.2008.008151 DOI: https://doi.org/10.1258/acb.2008.008151
  40. Mani LY, Nseir G, Venetz JP, Pascual M. Severe hypophosphatemia after intravenous administration of iron carboxymaltose in a stable renal transplant recipient. Transplantation. 2010 Oct;90(7):804–5. 10.1097/TP.0b013e3181f00a18 DOI: https://doi.org/10.1097/TP.0b013e3181f00a18
  41. Kalra PA, Bhandari S. Efficacy and safety of iron isomaltoside (Monofer®) in the management of patients with iron deficiency anemia. Int J Nephrol Renovasc Dis. 2016 Mar;9:53–64. 10.2147/IJNRD.S89704 DOI: https://doi.org/10.2147/IJNRD.S89704
  42. Kärnsund S, Lo B, Bendtsen F, Holm J, Burisch J. Systematic review of the prevalence and development of osteoporosis or low bone mineral density and its risk factors in patients with inflammatory bowel disease. World J Gastroenterol. 2020 Sep;26(35):5362–74. 10.3748/wjg.v26.i35.5362 DOI: https://doi.org/10.3748/wjg.v26.i35.5362
  43. Pepe J, Zawadynski S, Herrmann FR, Juillerat P, Michetti P, Ferrari-Lacraz S, et al. Structural Basis of Bone Fragility in Young Subjects with Inflammatory Bowel Disease: A High-resolution pQCT Study of the SWISS IBD Cohort (SIBDC). Inflamm Bowel Dis. 2017 Aug;23(8):1410–7. 10.1097/MIB.0000000000001139 DOI: https://doi.org/10.1097/MIB.0000000000001139
  44. Schüle S, Rossel JB, Frey D, Biedermann L, Scharl M, Zeitz J, et al.; Swiss IBD cohort study. Prediction of low bone mineral density in patients with inflammatory bowel diseases. United European Gastroenterol J. 2016 Oct;4(5):669–76. 10.1177/2050640616658224 DOI: https://doi.org/10.1177/2050640616658224
  45. Piodi LP, Poloni A, Ulivieri FM. Managing osteoporosis in ulcerative colitis: something new? World J Gastroenterol. 2014 Oct;20(39):14087–98. 10.3748/wjg.v20.i39.14087 DOI: https://doi.org/10.3748/wjg.v20.i39.14087
  46. Agrawal M, Arora S, Li J, Rahmani R, Sun L, Steinlauf AF, et al. Bone, inflammation, and inflammatory bowel disease. Curr Osteoporos Rep. 2011 Dec;9(4):251–7. 10.1007/s11914-011-0077-9 DOI: https://doi.org/10.1007/s11914-011-0077-9
  47. Lee N, Radford-Smith G, Taaffe DR. Bone loss in Crohn’s disease: exercise as a potential countermeasure. Inflamm Bowel Dis. 2005 Dec;11(12):1108–18. 10.1097/01.MIB.0000192325.28168.08 DOI: https://doi.org/10.1097/01.MIB.0000192325.28168.08
  48. van Bodegraven AA, Bravenboer N. Perspective on skeletal health in inflammatory bowel disease. Osteoporos Int. 2020 Apr;31(4):637–46. 10.1007/s00198-019-05234-w DOI: https://doi.org/10.1007/s00198-019-05234-w
  49. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al.; National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2014 Oct;25(10):2359–81. 10.1007/s00198-014-2794-2 DOI: https://doi.org/10.1007/s00198-014-2794-2
  50. Harbord M, Annese V, Vavricka SR, Allez M, Barreiro-de Acosta M, Boberg KM, et al.; European Crohn’s and Colitis Organisation. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis. 2016 Mar;10(3):239–54. 10.1093/ecco-jcc/jjv213 DOI: https://doi.org/10.1093/ecco-jcc/jjv213
  51. World Health Organization. WHO SCIENTIFIC GROUP ON THE ASSESSMENT OF OSTEOPOROSIS AT PRIMARY HEALTH CARE LEVEL Summary Meeting Report. 2004;
  52. Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011 Mar;22(3):809–16. 10.1007/s00198-010-1524-7 DOI: https://doi.org/10.1007/s00198-010-1524-7
  53. Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol. 2017 Feb;112(2):241–58. 10.1038/ajg.2016.537 DOI: https://doi.org/10.1038/ajg.2016.537
  54. Tome J, Sehgal K, Kamboj AK, Comstock B, Harmsen WS, Khanna S, et al. Budesonide Maintenance in Microscopic Colitis: Clinical Outcomes and Safety Profile From a Population-Based Study. Am J Gastroenterol. 2022 Aug;117(8):1311–5. 10.14309/ajg.0000000000001774 DOI: https://doi.org/10.14309/ajg.0000000000001774
  55. Yoon V, Maalouf NM, Sakhaee K. The effects of smoking on bone metabolism. Osteoporos Int. 2012 Aug;23(8):2081–92. 10.1007/s00198-012-1940-y DOI: https://doi.org/10.1007/s00198-012-1940-y
  56. Karban A, Eliakim R. Effect of smoking on inflammatory bowel disease: Is it disease or organ specific? World Journal of Gastroenterology: WJG. 2007 Apr 4. DOI: https://doi.org/10.3748/wjg.v13.i15.2150
  57. Williams KM, Darukhanavala A, Hicks R, Kelly A. An update on methods for assessing bone quality and health in Cystic fibrosis. J Clin Transl Endocrinol. 2021 Dec;27:100281. 10.1016/j.jcte.2021.100281 DOI: https://doi.org/10.1016/j.jcte.2021.100281
  58. Dubner SE, Shults J, Baldassano RN, Zemel BS, Thayu M, Burnham JM, et al. Longitudinal assessment of bone density and structure in an incident cohort of children with Crohn’s disease. Gastroenterology. 2009 Jan;136(1):123–30. 10.1053/j.gastro.2008.09.072 DOI: https://doi.org/10.1053/j.gastro.2008.09.072
  59. Schweizerische Gesellschaft für Rheumatologie. corticosteroid-OSTEOPOROSE: Vorbeugung und Behandlung. 2023.
  60. Maricic M, Deal C, Dore R, Laster A. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis: Comment on the Article by Buckley et al. Arthritis Care Res (Hoboken). 2018 Jun;70(6):949–50. 10.1002/acr.23424 DOI: https://doi.org/10.1002/acr.23424
  61. Glucocorticoid-Induced Osteoporosis Clinical Practice Guidelines.
  62. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, et al.; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev. 2002 Aug;23(4):508–16. 10.1210/er.2001-2002 DOI: https://doi.org/10.1210/er.2001-2002
  63. Melek J, Sakuraba A. Efficacy and safety of medical therapy for low bone mineral density in patients with inflammatory bowel disease: a meta-analysis and systematic review. Clin Gastroenterol Hepatol. 2014 Jan;12(1):32–44.e5. 10.1016/j.cgh.2013.08.024 DOI: https://doi.org/10.1016/j.cgh.2013.08.024
  64. Bakker SF, Dik VK, Witte BI, Lips P, Roos JC, Van Bodegraven AA. Increase in bone mineral density in strictly treated Crohn’s disease patients with concomitant calcium and vitamin D supplementation. J Crohns Colitis. 2013 Jun;7(5):377–84. 10.1016/j.crohns.2012.06.003 DOI: https://doi.org/10.1016/j.crohns.2012.06.003
  65. Frigstad SO, Høivik M, Jahnsen J, Dahl SR, Cvancarova M, Grimstad T, et al. Vitamin D deficiency in inflammatory bowel disease: prevalence and predictors in a Norwegian outpatient population. Scand J Gastroenterol. 2017 Jan;52(1):100–6. 10.1080/00365521.2016.1233577 DOI: https://doi.org/10.1080/00365521.2016.1233577
  66. Chatu S, Chhaya V, Holmes R, Neild P, Kang JY, Pollok RC, et al. Factors associated with vitamin D deficiency in a multicultural inflammatory bowel disease cohort. Frontline Gastroenterol. 2013 Jan;4(1):51–6. 10.1136/flgastro-2012-100231 DOI: https://doi.org/10.1136/flgastro-2012-100231
  67. Michaëlsson K, Melhus H, Warensjö Lemming E, Wolk A, Byberg L. Long term calcium intake and rates of all cause and cardiovascular mortality: community based prospective longitudinal cohort study. BMJ. 2013 Feb;346(7895):f228. 10.1136/bmj.f228 DOI: https://doi.org/10.1136/bmj.f228
  68. Lamy O, Stoll D, Aubry-Rozier B, Gonzalez Rodriguez E. Correction to: stopping Denosumab. Curr Osteoporos Rep. 2022 Oct;20(5):363. 10.1007/s11914-020-00565-8 DOI: https://doi.org/10.1007/s11914-020-00565-8
  69. Fernández Fernández E, Benavent Núñez D, Bonilla Hernán G, Monjo Henry I, García Carazo S, Bernad Pineda M, et al. Multiple vertebral fractures following discontinuation of denosumab treatment: ten clinical cases report. Reumatol Clin (Engl Ed). 2020;16(6):480–4. 10.1016/j.reumae.2018.11.021 DOI: https://doi.org/10.1016/j.reumae.2018.11.021
  70. Kurland ES, Heller SL, Diamond B, McMahon DJ, Cosman F, Bilezikian JP. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1–34)]. Osteoporosis International 2004 15:12. 2004 Jun 3;15(12):992–7. DOI: https://doi.org/10.1007/s00198-004-1636-z
  71. Kaufman JM, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky GP, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int. 2005 May;16(5):510–6. 10.1007/s00198-004-1713-3 DOI: https://doi.org/10.1007/s00198-004-1713-3